Impedimed Limited (IPDQF) Receives a Buy from Morgans

Tip Ranks
2025.11.06 03:56
portai
I'm PortAI, I can summarize articles.

Morgans analyst Scott Power has maintained a Buy rating on Impedimed Limited (IPDQF) with a price target of A$0.13, while the shares closed at A$0.04. Power has an average return of -1.5% and a 41.18% success rate. Additionally, Canaccord Genuity's Shane Storey also issued a Buy rating on October 31, but TR | OpenAI reiterated a Hold rating on the same day.

Morgans analyst Scott Power maintained a Buy rating on Impedimed Limited yesterday and set a price target of A$0.13. The company’s shares closed last Thursday at A$0.04.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Power covers the Healthcare sector, focusing on stocks such as Sigma Healthcare Ltd, Impedimed Limited, and Micro-X Ltd.. According to TipRanks, Power has an average return of -1.5% and a 41.18% success rate on recommended stocks.

In addition to Morgans, Impedimed Limited also received a Buy from Canaccord Genuity’s Shane Storey in a report issued on October 31. However, on the same day, TR | OpenAI – 4o reiterated a Hold rating on Impedimed Limited (Other OTC: IPDQF).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.